1 ion pgm platform: technology & sequencing applications mubasher “bash” dar, ph.d. sr....
TRANSCRIPT
1
Ion PGM Platform: Technology & Sequencing Applications
Mubasher “Bash” Dar, Ph.D.Sr. Applications ScientistThermo Fisher Scientific
2
Ion Technology Overview of Ion Torrent™ Sequencing Technology
Applications on Ion AmpliSeq (Multiplexing PCR and RT-PCR) Sequencing Data Other Sequencing Applications
Data Analysis• Primary Analysis (Torrent Suite from Ion)
• Secondary Analysis (Commercial Vendors)
Agenda
3
Personal Genome Machine® Sequencer & Chip
Easy, automatic fluid connections.Match the size of the Ion chip to your
application.
Low cost, convenient, single
use device.
4
PGM™ System Orientation
Touchscreen
Chip Compartment (chip clamp/squid)
Nucleotide bottles
Waste Bottle
Wash 3 Solution
Wash 2 Solution
Wash 1 Solution
5
Ion Workflow Overview
Prepare Library
Clonal AmplificationDNA / RNA
Data Analysis
Library Preparation
DNA Sequencing*
Isolate Positive Ion Sphere™ Particles
10
Data Analysis
Load Chip and Sequence
10
Template Preparation*
6
Scalability SpeedSimplicity
7
Ion Technology Core Principles
Scalability CMOS technology 40 years of Moore’s law
Simplicity Natural nucleotides No lasers No optics No camera No fluorescence No enzyme cascade
Speed Rapid detection of sequence
extension
The Chip is the Machine TM
8
Scalability: Semiconductor Technology
Wafer Chip Chip Cross Section
9
Simplicity: Natural Chemistry
10
Speed: Fast Direct Detection
DNA Ions Sequence Nucleotides flow sequentially over Ion semiconductor chip
One sensor per well per sequencing reaction
Direct detection of natural DNA extension
Millions of sequencing reactions per chip
Fast cycle time, real time detection
Rothberg J.M. et al Nature doi:10.1038/nature10242
Sensor Plate
Silicon SubstrateDrain SourceBulk
dNTP
To column receiver
∆ pH
∆ Q
∆ V
Sensing Layer
H+
11
Ion Torrent™ Workflow: Sequencing
12
Ion Workflow – PGM™ System Sequencing Run
Perform Sequencing Run4
Anneal Sequencing Primer1
Perform Polymerase Binding2
Load Ion Chip ™ Device3
PGM™ System Setup for 2 runs (200bp or less)
Initialize PGM™ System and Prepare Solutions
Perform PGM™ System CleaningDNAA
SequencingD
Template PrepC
CompatibleLibrary Prep
B
CompatibleData
E
13
Sequencing: Flows
Ion Sphere -----Primer------ A G T C A A G C G T C C C A T G
Sequence of InterestKey Sequence
T A C G T A C G T
Flows 1-4 …9-12Flows 5-8 … etc.T
A
C
GFlows 1-4
...---Ion Sphere™ Particle
• A “flow” is the event of exposing the chip to one particular dNTP (T, A, C, or G), followed by a washing step
• The flow order repeats with pattern: • ‘TACGTACGTCTGAGCATCGATCGATGTACAGC’
C G A CG T AC GT A
A “cycle” is four consecutive dNTP flows: for instance, T-A-C-G = 1 cycle
14
T
• A “flow” is the event of exposing the chip to one particular dNTP (T, A, C, or G), followed by a washing step
• The flow order repeats with pattern:• ‘TACGTACGTCTGAGCATCGATCGATGTACAGC’
Sequencing: Flows
Ion Sphere -----Primer------ A G T C A A G C G T C C C A T G
Sequence of InterestKey Sequence
C
T A C G T A C G T
Flows 1-4 …9-12Flows 5-8 … etc.T
A
C
G
Flows 5-8
...---Ion Sphere™ Particle
C G A CG T AC GT A
A “cycle” is four consecutive dNTP flows: for instance, T-A-C-G = 1 cycle
15
TIon Sphere -----Primer------ A G T C A A G C G T C C C A T G
Sequence of InterestKey Sequence
C
T A C G T A C G T C G A CG T AC G
Flows 1-4 …9-12Flows 5-8 … etc.T
C
G
T
Flows 9+
AG...---Ion Sphere™ Particle
• A “flow” is the event of exposing the chip to one particular dNTP (T, A, C, or G), followed by a washing step
• The flow order repeats with pattern:• ‘TACGTACGTCTGAGCATCGATCGATGTACAGC’
T
T A
A “cycle” is four consecutive dNTP flows: for instance, T-A-C-G = 1 cycle
Sequencing: Flows
16
TIon Sphere -----Primer------ A G T C A A G C G T C C C A T G
Sequence of InterestKey Sequence
AC G
T A C G T A C G T
Flows 1-4 …9-12Flows 5-8 … etc.T
A
C
G
T
T T CGCA GGGT AC
And so on…
...---Ion Sphere™ Particle
• A “flow” is the event of exposing the chip to one particular dNTP (T, A, C, or G), followed by a washing step
• The flow order repeats with pattern:• ‘TACGTACGTCTGAGCATCGATCGATGTACAGC’
C G A CG T AC GT A
A “cycle” is four consecutive dNTP flows: for instance, T-A-C-G = 1 cycle
Sequencing: Flows
17
Throughput of PGM Sequencer -- Chip type Reads
18
Ion PGM™ Metrics
Ion 314™ Chip
Ion 316™ Chip
Ion 318™ Chip
Ion PGM™ Chip Ion User Q20 bases
314 cnservice.ion 167,753,95
316 Corebotz 789,113,176
318 cnservice.ion 1,355,996,615
External PerformanceWell Beyond Spec(Ion CommunityRecogntION Runs)
19
Ion Torrent™ Workflow: Template Prep
20
Ion Workflow – Template Prep
Enrich – Ion OneTouch™ ES
DNAA
SequencingD
Template Prep
C
CompatibleLibrary Prep
B
CompatibleData
E
Qubit ®Fluorometer
Total Processing Time ~5-8 hoursHands-On Time ~25 min.
Amplify, recover – Ion OneTouch™ 2 Instrument
3
Assemble amplification reaction
2
1
21
Ideal Clonal Amplification
Amplification
10
10
10
10
10
10 1 0
10
1 010
10
Expanded view
PrimersdNTPsPolymeraseMgCl2
22
PostAmplification
Add MagneticStreptavidin Bead
Immobilize to Magnet and Wash
Denature ISP with NaOH
*
*This species can be minimized through proper dilution. Proper DNA to Ion Sphere™ Particle ratio is critical!
Ion Sphere™ Particle Enrichment
23
Ion Torrent™ Workflow: Library Prep & Ion PGM Publications Data
24
Ion AmpliSeq Technology – Multiplexing PCR and RT-PCR
AmpliSeq DNA
Ready-to-Go Panel (e.g. Cancer)
Custom Panels (Any Genes)150, 200 or 375bp
AmpliSeq RNA
Ready-to-Go Panel (cancer & Lung)
• 150bp panels are FFPE compatible• 10ng of DNA or RNA required
Whole Transcriptome
Whole Exome
25
Ion AmpliSeq™ Library Workflow
• Prepare your samples using standard PCR techniques
• Starting with just 10 ng of input DNA – compatible with FFPE samples
• Leverage Ready-to-Use panels or build your own Custom panel
26
Ion AmpliSeq™ Ready-To-Use Panels
Cancer Hotspot Panel v2
50 genes >2,800 COSMIC Mutations 207 Amplicons
Comprehensive Cancer Panel
409 Genes 16,000 Amplicons
Inherited Disease Panel
700 Diseases 328 Genes 10,000 Amplicons
www.ampliseq.com
Custom AmpliSeq Panel of your genes
27
Ion PGM™ Sequencer leads the market in SNP accuracy (>90% of variation)
28
PGM Sensitivity and Mutation Detection
Mutation Type
PGM Sensitivity
SNP 1-5%
INDELS 20%
29
Sequencing of circulating cell free DNA suggests non-invasive profiling could be used instead of metastatic biopsies
• Circulating cell free DNA (cfDNA) profiled using the Ion AmpliSeq™ Cancer Hotspot PanelInstead of metastatic biopsies, sequencing on the Ion PGM™ System was used to screen metastatic breast cancer tumor (n=69) and serum (n=31) samples from 17 patients
• Allele frequencies as low as 0.5% were detected 13 out of 17 (76%) had concordant tumor and plasma mutation findings
• 92% of findings validatedIllumina technology was used to confirm 77 (92%) out of 84 samples tested. Two patient’s tumor mutations were detected in the plasma by Illumina sequencing that were not detected by Ion Torrent sequencing
• Rapid, cost-effective and non-invasive method could improve patient screening“This represents a non‐invasive approach, at a reasonable cost, with a quick turnaround time. Consequently, it might increase patient access to molecular screening programs and lead to personalized treatment approaches.”
http://annonc.oxfordjournals.org/content/early/2014/07/25/annonc.mdu288.abstract
30
Sequencing platform comparison for solid tumor genomic biomarker discovery
• Solid tumor genomic biomarker discoveryProspective phase I clinical trail patients samples were sequenced
• Sequencing platform comparison27 samples (FFPE and fresh frozen) were compared between the MiSeq (TruSeq Amplicon Cancer Panel) and the Ion PGM™ System (Ion AmpliSeq™ Cancer Hotspot Panel) as well as Sequenom MassARRAY (OncoCarta 1.0)
• 97% concordance between MiSeq and PGM variant callsAt an allele frequency ≥13% and depth of coverage of ≥500% (found 91% concordance between MiSeq and Sequenom). 21 out of 27 samples showed a 100% concordance (78%) between MiSeq and PGM
• Similar variant allele frequencies between MiSeq and PGM “Variant allele frequencies of gene mutations detected on both NGS platforms were strikingly similar.”
• Actionable mutation discovery57% patients (53 out of 93) were allocated clinical trials due to actionable mutations
http://dx.doi.org/10.1038/bjc.2014.350
31
Evaluation of a New High-Throughput Next-Generation Sequencing Method Based on a Custom AmpliSeq Library and Ion Torrent PGM Sequencing for the Rapid Detection of Genetic Variations in Long QT Syndrome• Custom AmpliSeq™ panel and the Ion PGM™
System were used for rapid variant detection in long QT syndrome
• The AmpliSeq™ panel was designed to the five most prevalent cardiomyopathy-causing genes (KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2)
• Covering 86% of the targeted regions
• Using 30 previously characterized samples, all variants (40 SNVs, 17 indels) were detected
• NextGENe v.2.3.4 (SoftGenetics) & Alamut 2.3.6 were used for further signal processing, base calling, sequence alignment, and variant analysis
• The future: • “Studies are ongoing to improve this approach by obtaining a
more complete, faster, and cheaper molecular exploration of patients presenting with LQTS. First of all, use of either an Ion 318TM (PGM sequencer) or PITM (Proton sequencer) chips would allow analysis of more patients simultaneously in the same run. Secondly, as illustrated by the recent availability of the AmpliSeqTM exome, improvement of algorithms used by the AmpliSeqTM designer would allow exploration of an increasing number of LQTS-causing genes, for which all targeted sequences will be efficiently covered.”
http://dx.doi.org/10.1007/s40291-014-0099-y
32
Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations
• Evaluation of AmpliSeq™ Cancer Hotspot Panel v2 for somatic mutation detection
• Samples used: cell line DNA; FFPE cell line DNA with genetically engineered mutations; FFPE samples with known mutations
• “Our results suggest that >100× coverage is needed to identify somatic mutation results with confidence.”
• Accuracy studies demonstrated 100% concordance
• Variant concordance was >95% between runs
• “The sources of disparity between variants called for the same library across the three chips were low variant frequency and homopolymeric sequences, both easily masked based on our decision tree.”
• Limit of detection was found to be 5% for SNVs and 20% for indels
• “Importantly, we were able to identify two additional actionable EGFR mutations (T790M) from this cohort that are not included in our single gene assay as it currently stands.”
• “We also showed that input DNA concentrations well below those recommended by the manufacturer could result in adequate sequencing reactions. We have tailored the runs to produce robust analyses with available starting material of as little as 1 ng of DNA isolated from FFPE tissue.
http://dx.doi.org/10.1515/cclm-2013-0883
33
Hereditary hearing loss: a 96 gene targeted sequencing protocol reveals novel alleles in a series of Italian and Qatari patients
• Custom AmpliSeq™ panel targeting 96 genes implicated in hereditary hearing loss was sequenced using the Ion PGM™ System• Planned release as a Community Panel
• 12 families from Italy and Qatar were assessed with detection of a pathogenic mutation identified in 4 families (33%)
• Five novel alleles were uncovered in LOXHD1, TMPRSS3, TECTA, and MYO15A
• SNVs and indels with Q<20 were filtered
• SNVs present in dbSNP, with recessive pattern of inheritance and MAF>0.03, and dominant mode of inheritance were excluded
• Missense mutations were assessed using in silico tools PolyPhen-2 and MutationTaster
http://www.sciencedirect.com/science/article/pii/S037811191400328X
34
Custom AmpliSeq™ panel demonstrates efficient large gene genotyping and copy number detection• Common autosomal dominant disorder
Dominant loss-of-function mutations in tumor suppressor neurofibromatosis type 1 (NF1) affects ~1/3000 individuals with ~50% sporadic de novo mutations
• Challenging geneNF1 is a sequencing challenge due to its large size, multiple identical pseudo genes, and lack of mutational hotspots
• Custom AmpliSeq™ panel sequenced efficiently on the Ion PGM™ System48 barcoded samples were sequenced on an Ion 316™ Chip with 96% of targeted bases covered 100x. The custom AmpliSeq™ panel targeted 100% and 98.8% coding region of SPRED1 and NF1 genes, respectively
• 100% mutation detectionUsing a validation set of 30 samples with known mutations
• Prospective testing identifies SNVs and CNVsFound NF1 alterations in 88% of samples (246/279) and SPRED1 and NF1 found in 92% (256/279).
http://dx.doi.org/10.1038/ejhg.2014.145
Dilution experiments demonstrate good correspondence between theoretical and observed mutant allele frequencies
35
36
Ion RNA AmpliSeq™ Ready-To-Use Panels
RNA Apoptosis Panel
267 genesTaqMan® validated
RNA Cancer Panel50 genesCorresponds to genes in Ion AmpliSeq™ Cancer Hotspot v2
RNA Custom PanelTarget any gene300 genes in single tube
www.ampliseq.com
37
AmpliSeq RNA panel aids expression study of 917 iPSC-related genes with improved detection of low abundance transcripts
• Roche team validates custom AmpliSeq
RNA panel 917 human genes targeted representing ~150
biological signaling cascades sequenced on the Ion
Proton™ System
• Stem cell differentiation model systemInduced pleuripotent stem cells (iPSC) differentiated to
cardiomyocytes used to assess custom AmpliSeq™
RNA panel
• Comparison to microarray and RNA-seqILMN Human Beadchip and Ion Proton™ System RNA-
Seq data generated for comparison
• AmpliSeq RNA panels fill important
research gap“Adaptation of AmpliSeq-RNA technology to high-
performance semiconductor technology closes an
important gap in custom RNA analysis because it
allows for the first time multi-parallel expression
analysis of hundreds of genes in up to one hundred
samples covering a dynamic range of five orders of
magnitude.”
AmpliSeq RNA-only DEGs
PM:24997760
38
39
Ion PGM – other library types
• 16S ribosomal RNA profiling (bacteria typing)• ChIP-Seq• Viral (RNA and DNA) Sequencing – HIV & Flu• Mitochondrial DNA sequencing• Microbial Sequencing• Reproductive Medicine (Targeted gene sequencing)• microRNA (50% of known miRNA in mirBASE detected)
40
41
16S rRNA profiling of meconium identifies bacteria correlated with premature birth
• 16S rRNA profiling on the Ion PGM™ System was used to characterize microbial communities present on meconiumMeconium is a substance that lines the fetal intestines resulting from ingestion in utero. Meconium stool is passed by a newborn soon after birth, before an infant has started to digest breast milk
• Bacteria correlated with premature birthMeconium from 52 infants was characterized and analysis identified: “Enterobacter, Enterococcus, Lactobacillus, Photorhabdus, and Tannerella, were negatively correlated with gestational age and have been reported to incite inflammatory responses, suggesting a causative role in premature birth.”
• Gestational age has largest impact on the mecomium microbiome With mode of delivery (natural v. c-section) also having a large effect
http://dx.doi.org/10.1371%2Fjournal.pone.0090784
Behind the Bench blog post:http://ioncommunity.lifetechnologies.com/community/behindthebench/blog/2014/05/23/microbial-community-analysis-via-16s-rrna-profiling
42
Torrent Suite™ to Generate BAM Files for Analysis
WELLSInstrumentUnmapped
BAM
SFF
BAM
FASTQ
VCF
Variant Calling
43
Kit Type % Q30 Reads
200bp Sequencing
64-68%
400bp Sequencing
57%
Error Rates on PGM and chemistry type
44
45
46
For Research Use Only. Not for use in diagnostic procedures.
Life Technologies is a Thermo Fisher Scientific brand. © 2014 Thermo Fisher Scientific, Inc. All rights reserved. TaqMan is a registered trademark of Roche Molecular Systems,
Inc., used under permission and license. All other trademarks are the property of Thermo Fisher Scientific and its subsidiaries.